Aclarion, Inc. director and CEO Brent Ness reported an open-market purchase of company stock. He bought 6,289 shares of Common Stock on the public market at a price of $3.18 per share. After this transaction, he directly owns 6,300 shares of Aclarion Common Stock.
Aclarion, Inc. director William Wesemann bought shares of the company in the open market. On 5/6/2026, he completed an open-market purchase of 1,562 shares of Aclarion common stock at a price of $3.30 per share. After this transaction, his direct holdings total 1,563 common shares.
Aclarion, Inc. has authorized a stock repurchase program of up to $2.5 million of its outstanding common shares. The company expects to carry out repurchases over the next 12 months, using methods such as open market purchases, block trades, privately negotiated deals, and 10b5-1 plans.
Aclarion plans to fund the program with existing cash and cash equivalents. As of March 31, 2026, it held approximately $19.0 million in cash and cash equivalents, which management believes is sufficient to support operations through key milestones, including the initial milestone of the CLARITY randomized trial.
Management describes the buyback as part of disciplined capital allocation and states they believe the current share price does not fully reflect the company’s Nociscan platform and long-term growth opportunity. The program is flexible and may be suspended, modified, or discontinued at any time.
SEG Opportunity Fund, LLC reports beneficial ownership of 244,043 shares of Aclarion, Inc. common stock, equal to 9.98% of the class. The filing states this position is based on 2,444,871 shares outstanding as of March 25, 2026. The statement lists shared voting and dispositive power over the 244,043 shares and is signed by Joseph Reda as Manager.
Aclarion, Inc. adopted a limited-duration stockholder rights plan that issues one right for each share of common stock and each Rights-Eligible Warrant outstanding as of March 30, 2026. Each right lets holders buy one one-thousandth of a share of Series D Junior Participating Preferred Stock at $14.00, subject to adjustment.
The plan is triggered if a person or group acquires 10% or more of common stock without board approval, with existing holders at or above that level grandfathered so long as they do not increase ownership. If triggered, other holders can buy securities at a 2x value multiple, diluting the acquirer.
The plan expires on March 18, 2027 unless earlier redeemed for $0.001 per right, exchanged into common or preferred shares, or terminated in connection with a board-approved merger. Aclarion also designated 10,000 shares of Series D Junior Participating Preferred Stock to support the plan.
Gregory A. Gould, Chief Financial Officer of Aclarion, Inc. (ticker shown as ACON), reported an option grant on a Form 4 filed 09/03/2025 for a transaction dated 09/02/2025. The filing shows an award of 17,000 stock options with an exercise price of $7.15. The options are reported as directly held and the underlying common stock amount is 17,000 shares.
The filing explains the vesting schedule: 25% vests on September 2, 2026, and the remaining 75% vests in 36 equal monthly installments thereafter. The derivative shows an expiration or related date of 09/02/2035 in the table and the reporting person signed the form on 09/03/2025.
Gregory A. Gould, who is listed as an officer (CFO) and director of Aclarion, Inc. (ACON), filed an initial Form 3 reporting event dated 09/02/2025. The filing states that Mr. Gould does not beneficially own any securities of the issuer at the time of the report. The form provides his business address in Broomfield, Colorado, and is signed 09/03/2025.
Aclarion, Inc. disclosed the appointment of Gregory A. Gould as Chief Financial Officer with an employment agreement effective September 1, 2025. The filing references an employment agreement and a related press release dated September 3, 2025, indicating the company has completed the executive hiring step and made public communications about the change. The notice identifies the role, the named officer, and the cited exhibits but does not include compensation details, background biography, or forward guidance.
Aclarion, Inc. reported results for the quarter ended June 30, 2025. Cash and cash equivalents were $12,850,657 (including $11,949,908 in money market funds), which management believes funds operations into the third quarter of 2026. Revenue grew to $19,319 in Q2 2025 (up 76% year-over-year) and $38,309 for the six months (up 82%), driven by increased NOCISCAN report volume in the U.K. Q2 gross profit was $5,140, but operating expenses rose to $1.74 million, producing a Q2 net loss of $1.60 million and a six-month net loss of $3.64 million. In H1 2025 the company raised approximately $20.1 million via a public unit offering, two registered direct offerings and warrant exercises. Corporate actions included two 2025 reverse stock splits and the $1,213,590 redemption of Series B preferred stock. The company recorded a $687,500 settlement in March 2025. Readers should consult the full notes for detailed terms of warrants, preferred conversions, and cash assumptions.